Delving into the Latest Updates on NM-6606 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

+ [1]

Target

RXRA

Mechanism

RXRA agonists(Retinoid X receptor alpha agonists)

Therapeutic Areas

Digestive System Disorders

Active Indication

Nonalcoholic Steatohepatitis

Inactive Indication-

Originator Organization

Tengji (Xiamen) Biomedical Technology Co., Ltd.

Active Organization

Tengji (Xiamen) Biomedical Technology Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

1.评估ACT500在健康成年受试者中单次和多次口服给药的安全性和耐受性； 2.评估ACT500及其代谢物在健康成年受试者中单次和多次口服给药的药代动力学（PK）特征； 3.探索ACT500在健康成年受试者中单次和多次口服给药的代谢产物和生物标志物。

[Translation]

1. Evaluate the safety and tolerability of ACT500 after single and multiple oral administration in healthy adult subjects; 2. Evaluate the pharmacokinetic (PK) characteristics of ACT500 and its metabolites after single and multiple oral administration in healthy adult subjects; 3. Explore the metabolites and biomarkers of ACT500 after single and multiple oral administration in healthy adult subjects.

Start Date-

Sponsor / Collaborator

Tengji (Xiamen) Biomedical Technology Co., Ltd.

100 Clinical Results associated with NM-6606

Login to view more data

100 Translational Medicine associated with NM-6606

Login to view more data

100 Patents (Medical) associated with NM-6606

Login to view more data

100 Deals associated with NM-6606

Login to view more data